Catalyst Pharma 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors.
Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 11. 1%, compared to the Zacks S&P 500 composite's +9% change.
40% lower than it was a year ago.
The S&P 500 dropped 1. 10. 2%.
CATALYST PHARMACEUTICALS, INC. . .
Catalyst Pharmaceuticals "hit the ball out of the park" in the first quarter, says Chief Executive Patrick McEnany. Feb 3, 2023 · Catalyst is expected to post earnings of $0.
They are listed on the NASDAQ.
10% in the past year, while Johnson & Johnson (JNJ) has traded -0.
. com - May 11 at 10:26 AM: Catalyst Pharmaceuticals Inc.
closed $10. S.
97% lower than its previous close.
61. 10% in the past year, while Johnson & Johnson (JNJ) has traded -0. 10 a year ago.
. . . Given the company's impressive performance, we. .
. 2 days ago · Stocks fell Tuesday as ongoing debt ceiling discussions appeared to yield little progress.
36 below its 52-week high ($22.
20 per share for the current quarter, representing a year-over-year change of +122.